1. In Vivo
  2. >>Innovation

Gen AI Companies Shine In Drug Development

 
• By David Wild

A string of AI-focused deals in 2023 and two late-year gen AI-specific agreements may presage a strong 2024 for drug discovery companies employing AI. 

Bio Bytes
• Source: Shutterstock

In early December, AstraZeneca PLC announced a $247m alliance with generative artificial intelligence biologics development company, AbSci Corp., to design an antibody against an unnamed oncology target, while Boehringer Ingelheim GmbH inked a deal of undisclosed value with Ten63 Therapeutics, also a gen AI-guided company that has focused on oncology to date. 

Could these two deals be a preview for a strong year ahead for gen AI-drive drug discovery companies? The technology, while new, is appealing in several ways. Gen AI can be trained on large datasets to identify rules and patterns not necessarily seen through other methods and then generate its own datasets, so it can be a fruitful approach for de novo drug creation

More from Innovation

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.